Trials / Completed
CompletedNCT02888080
Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
A Multiple-dose, Subject and Investigator Blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885(Canakinumab) in Patients With Pulmonary Sarcoidosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess if ACZ885 will improve lung function in association with reduction of tissue inflammation in patients with chronic sarcoidosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACZ885 | ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months. |
| DRUG | Placebo | Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months. |
Timeline
- Start date
- 2016-12-19
- Primary completion
- 2019-03-04
- Completion
- 2019-03-04
- First posted
- 2016-09-02
- Last updated
- 2021-10-04
- Results posted
- 2020-03-16
Locations
8 sites across 3 countries: United States, Germany, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02888080. Inclusion in this directory is not an endorsement.